Synergistic orphan disease product candidates that bridge the treatment gap

A novel product candidate that eliminated pancreatic cancer tumors and their metastases in mouse models

Dysfunctional glycosylation leads to vicious cycle…

• Protein misfolding

• Genetic instability, evolving mutations

• Multiple vulnerability pathways that cancers exploit.

• Pathways include proliferative signaling, invasion, metastasis, apoptosis resistance, and angiogenesis

​

Anviron is developing revolutionary & novel small molecules that target and disrupts the first step in glycosylation, leading to:   

• Disruption of chronic proliferation signaling

• Disruption of anti-apoptosis signaling

• Deactivating cell invasiveness, migration and metastasis

            With low observed toxicity*

Novel finding: Our product candidate promoted cancer cell differentiation to mature phenotypes more vulnerable to other cytotoxic therapies.

"All tumors were significantly reduced in two weeks." - Michio Kurosu, PhD University of Tennessee Health Science Center